{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T22:41:56Z","timestamp":1722897716670},"reference-count":175,"publisher":"Wiley","issue":"8a","license":[{"start":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T00:00:00Z","timestamp":1244678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>The myeloproliferative neoplasms<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The molecular pathogenesls of MPN<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Epigenetic events In cancer<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Epigenetic events In MPN<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Drugs for epigenetic therapy<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Epigenetic therapy In MPN<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Conclusions<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><jats:p>The classic Philadelphia chromosome\u2010negative myeloproliferative neoplasms (MPNs), which include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis, originate from a stem cell\u2010derived clonal myeloproliferation that manifests itself with variable haematopoietic cell lineage involvement; they are characterized by a high degree of similarities and the chance to transform each to the other and to evolve into acute leukaemia. Their molecular pathogenesis has been associated with recurrent acquired mutations in janus kinase 2 (JAK2) and myeloproliferative leukemia virus oncogene (MPL). These discoveries have simplified the diagnostic approach and provided a number of clues to understanding the phenotypic expression of MPNs; furthermore, they represented a framework for developing and\/or testing in clinical trials small molecules acting as tyrosine kinase inhibitors. On the other hand, evidence of abnormal epigenetic gene regulation as a mechanism potentially contributing to the pathogenesis and the phenotypic diversity of MPNs is still scanty; however, study of epigenetics in MPNs represents an active field of research. The first clinical trials with epigenetic drugs have been completed recently, whereas others are still ongoing; results have been variable and at present do not allow any firm conclusion. Novel basic and translational information concerning epigenetic gene regulation in MPNs and the perspectives for therapy will be critically addressed in this review.<\/jats:p>","DOI":"10.1111\/j.1582-4934.2009.00827.x","type":"journal-article","created":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T23:09:44Z","timestamp":1244761784000},"page":"1437-1450","source":"Crossref","is-referenced-by-count":16,"title":["Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives"],"prefix":"10.1111","volume":"13","author":[{"given":"Alessandro M.","family":"Vannucchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costanza","family":"Bogani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,23]]},"reference":[{"key":"e_1_2_9_2_2","volume-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"Swertllow SH","year":"2008"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2003.50026"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01038.x"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra063728"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2210"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2006.11.005"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20009"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.177"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.12.002"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.07.004"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.062"},{"key":"e_1_2_9_22_2","first-page":"29","article-title":"Primary myelofibrosis","volume":"142","author":"Tefferi A","year":"2008","journal-title":"Cancer Treat Res."},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2005.01.001"},{"key":"e_1_2_9_25_2","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk PD","year":"1986","journal-title":"Semin Hematol."},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-9-199511010-00003"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_2_9_28_2","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman SM","year":"1997","journal-title":"Semin Hematol."},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198102193040801"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(03)00080-7"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.72"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405080"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3917"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.280"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-008-9025-4"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.195"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4824"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002030"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2210"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000018"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107748"},{"key":"e_1_2_9_47_2","doi-asserted-by":"crossref","unstructured":"ShideK ShimodaHK KumanoT et al.Development of ET primary myelofibrosis and PV in mice expressing JAK2 V617F Leukemia.2007;22:87\u201395.","DOI":"10.1038\/sj.leu.2405043"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404379"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404086"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005751"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404405"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101576"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06565.x"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-131664"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-135897"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.137"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06348.x"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.69"},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13266"},{"key":"e_1_2_9_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.1"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.11.012"},{"key":"e_1_2_9_63_2","doi-asserted-by":"crossref","first-page":"lba","DOI":"10.1182\/blood.V112.11.lba-3.lba-3","article-title":"TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a pre\u2010JAK2 V617F event","volume":"112","author":"Delhommeau F","year":"2008","journal-title":"Blood."},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095703"},{"key":"e_1_2_9_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3310230"},{"key":"e_1_2_9_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/embo-reports\/kve022"},{"key":"e_1_2_9_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.159"},{"key":"e_1_2_9_69_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072067"},{"key":"e_1_2_9_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2005"},{"key":"e_1_2_9_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddm018"},{"key":"e_1_2_9_72_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1232504"},{"key":"e_1_2_9_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1598"},{"key":"e_1_2_9_74_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083557"},{"key":"e_1_2_9_75_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083558"},{"key":"e_1_2_9_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/46052"},{"key":"e_1_2_9_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023075"},{"key":"e_1_2_9_78_2","first-page":"3225","article-title":"A gene hypermethylation profile of human cancer","volume":"61","author":"Esteller M","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_9_79_2","first-page":"798","article-title":"Methylation\u2010associated silencing of the tissue inhibitor of metalloproteinase\u20103 gene suggest a suppressor role in kidney, brain, and other human cancers","volume":"59","author":"Bachman KE","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_9_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg816"},{"key":"e_1_2_9_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/5047"},{"key":"e_1_2_9_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00045-5"},{"key":"e_1_2_9_83_2","doi-asserted-by":"publisher","DOI":"10.1242\/dev.002006"},{"key":"e_1_2_9_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03315"},{"key":"e_1_2_9_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1997"},{"key":"e_1_2_9_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.01.014"},{"key":"e_1_2_9_87_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506654102"},{"key":"e_1_2_9_88_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328303e15d"},{"key":"e_1_2_9_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136218"},{"key":"e_1_2_9_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.09.023"},{"key":"e_1_2_9_91_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.9.4209"},{"key":"e_1_2_9_92_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4218"},{"key":"e_1_2_9_93_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1165395"},{"key":"e_1_2_9_94_2","first-page":"2120A","article-title":"A high resolution epigenomic map of myelofibrosis reveals multiple chromosomal deletions and amplifications accompanied by a high level of functionally important methylation","volume":"110","author":"Opalinska J","year":"2006","journal-title":"Blood."},{"key":"e_1_2_9_95_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802527699"},{"key":"e_1_2_9_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.12.017"},{"key":"e_1_2_9_97_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-039735"},{"key":"e_1_2_9_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0501-4"},{"key":"e_1_2_9_99_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04660.x"},{"key":"e_1_2_9_100_2","first-page":"42","article-title":"The suppressor of cytokine signaling\u20101 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon\u2010alpha","volume":"89","author":"Roman\u2010Gomez J","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_9_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23694"},{"key":"e_1_2_9_102_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13043"},{"key":"e_1_2_9_103_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07072.x"},{"key":"e_1_2_9_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.03.014"},{"key":"e_1_2_9_105_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10222"},{"key":"e_1_2_9_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05107.x"},{"key":"e_1_2_9_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20886"},{"key":"e_1_2_9_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06293.x"},{"key":"e_1_2_9_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404513"},{"key":"e_1_2_9_110_2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V95.8.2569","article-title":"Cloning of PRV\u20101, a novel member of the uPAR receptor superfamily which is over\u2010expressed in polycythemia rubra vera","volume":"95","author":"Temerinac S","year":"2000","journal-title":"Blood."},{"key":"e_1_2_9_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.09.008"},{"key":"e_1_2_9_112_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3249"},{"key":"e_1_2_9_113_2","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2006-0351"},{"key":"e_1_2_9_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2007.01.003"},{"key":"e_1_2_9_115_2","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2008-0377"},{"key":"e_1_2_9_116_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0572"},{"key":"e_1_2_9_117_2","doi-asserted-by":"crossref","first-page":"101A","DOI":"10.1182\/blood.V112.11.101.101","article-title":"Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin modifying agents","volume":"112","author":"Wang X","year":"2008","journal-title":"Blood."},{"key":"e_1_2_9_118_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1860"},{"key":"e_1_2_9_119_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-007377"},{"key":"e_1_2_9_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.08.020"},{"key":"e_1_2_9_121_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12706"},{"key":"e_1_2_9_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.08.021"},{"key":"e_1_2_9_123_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9679"},{"key":"e_1_2_9_124_2","first-page":"21","article-title":"Effects of treatment with 5\u2010azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes","volume":"7","author":"Silverman LR","year":"1993","journal-title":"Leukemia."},{"key":"e_1_2_9_125_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"e_1_2_9_126_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404050"},{"key":"e_1_2_9_127_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078576"},{"key":"e_1_2_9_128_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"e_1_2_9_129_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021162"},{"key":"e_1_2_9_130_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.981"},{"key":"e_1_2_9_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22470"},{"key":"e_1_2_9_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1272"},{"key":"e_1_2_9_133_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500369102"},{"key":"e_1_2_9_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1238"},{"key":"e_1_2_9_135_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-098061"},{"key":"e_1_2_9_136_2","doi-asserted-by":"crossref","first-page":"7000A","DOI":"10.1200\/jco.2008.26.15_suppl.7000","article-title":"A phase I\/II study of vorinostat, an oral histone deacethylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndromes and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium","volume":"26","author":"Silverman LR","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_9_137_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4333"},{"key":"e_1_2_9_138_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22891"},{"key":"e_1_2_9_139_2","first-page":"986","article-title":"Valproic acid and all\u2010trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia","volume":"90","author":"Raffoux E","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_9_140_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21132"},{"key":"e_1_2_9_141_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21589"},{"key":"e_1_2_9_142_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404860"},{"key":"e_1_2_9_143_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052702999"},{"key":"e_1_2_9_144_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-014126"},{"key":"e_1_2_9_145_2","doi-asserted-by":"crossref","first-page":"1175A","DOI":"10.1182\/blood.V110.11.1175.1175","article-title":"A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results","volume":"110","author":"Galli M","year":"2007","journal-title":"Blood."},{"key":"e_1_2_9_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.031"},{"key":"e_1_2_9_147_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20869"},{"key":"e_1_2_9_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2006.08.028"},{"key":"e_1_2_9_149_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04303"},{"key":"e_1_2_9_150_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm024"},{"key":"e_1_2_9_151_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1582"},{"key":"e_1_2_9_152_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2538"},{"key":"e_1_2_9_153_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002236"},{"key":"e_1_2_9_154_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004029"},{"key":"e_1_2_9_155_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.91"},{"key":"e_1_2_9_156_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.136"},{"key":"e_1_2_9_157_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_9_158_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gnh032"},{"key":"e_1_2_9_159_2","doi-asserted-by":"crossref","first-page":"2809A","DOI":"10.1182\/blood.V112.11.2809.2809","article-title":"Phase II trial of low dose, subcutaneous decitabine in myelofibrosis","volume":"112","author":"Odenike OM","year":"2008","journal-title":"Blood."},{"key":"e_1_2_9_160_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405049"},{"key":"e_1_2_9_161_2","doi-asserted-by":"crossref","first-page":"100A","DOI":"10.1182\/blood.V112.11.100.100","article-title":"A phase 2A study of the histone\u2010deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms","volume":"112","author":"Rambaldi A","year":"2008","journal-title":"Blood."},{"key":"e_1_2_9_162_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0640-3"},{"key":"e_1_2_9_163_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1104-7"},{"key":"e_1_2_9_164_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.83"},{"key":"e_1_2_9_165_2","first-page":"6039","article-title":"Reversal of drug resistance in human tumor xenografts by 2\u2019\u2010deoxy\u20105\u2010azacyti\u2010dine\u2010induced demethylation of the hMLH1 gene promoter","volume":"60","author":"Plumb JA","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_9_166_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4074"},{"key":"e_1_2_9_167_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2303"},{"key":"e_1_2_9_168_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404948"},{"key":"e_1_2_9_169_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-9796(03)00015-9"},{"key":"e_1_2_9_170_2","first-page":"230","article-title":"Calcitonin gene methylation in chronic myeloproliferative disorders","volume":"8","author":"Ihalainen J","year":"1994","journal-title":"Leukemia."},{"key":"e_1_2_9_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.11.002"},{"key":"e_1_2_9_172_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2001.03319.x"},{"key":"e_1_2_9_173_2","first-page":"1147","article-title":"Mutations and promoter methylation status of NPM1 in myeloproliferative disorders","volume":"91","author":"Oki Y","year":"2006","journal-title":"Haematologica."},{"key":"e_1_2_9_174_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207510"},{"key":"e_1_2_9_175_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.06.010"},{"key":"e_1_2_9_176_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03215.x"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1582-4934.2009.00827.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1582-4934.2009.00827.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:49:09Z","timestamp":1697316549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1582-4934.2009.00827.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":175,"journal-issue":{"issue":"8a","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1582-4934.2009.00827.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00827.x","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"value":"1582-1838","type":"print"},{"value":"1582-4934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}